17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Exon-specific U1 snRNAs improve ELP1 exon 20 definition and rescue ELP1 protein expression in a familial dysautonomia mouse model

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Familial dysautonomia (FD) is a rare genetic disease with no treatment, caused by an intronic point mutation (c.2204+6T>C) that negatively affects the definition of exon 20 in the elongator complex protein 1 gene ( ELP1 also known as IKBKAP). This substitution modifies the 5′ splice site and, in combination with regulatory splicing factors, induces different levels of exon 20 skipping, in various tissues. Here, we evaluated the therapeutic potential of a novel class of U1 snRNA molecules, exon-specific U1s (ExSpeU1s), in correcting ELP1 exon 20 recognition. Lentivirus-mediated expression of ELP1-ExSpeU1 in FD fibroblasts improved ELP1 splicing and protein levels. We next focused on a transgenic mouse model that recapitulates the same tissue-specific mis-splicing seen in FD patients. Intraperitoneal delivery of ELP1-ExSpeU1s-adeno-associated virus particles successfully increased the production of full-length human ELP1 transcript and protein. This splice-switching class of molecules is the first to specifically correct the ELP1 exon 20 splicing defect. Our data provide proof of principle of ExSpeU1s-adeno-associated virus particles as a novel therapeutic strategy for FD.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Modeling Pathogenesis and Treatment of Familial Dysautonomia using Patient Specific iPSCs

          SUMMARY The isolation of human induced pluripotent stem cells (iPSCs)1-3 offers a novel strategy for modeling human disease. Recent studies have reported the derivation and differentiation of disease-specific human iPSCs4-7. However, a key challenge in the field is the demonstration of disease-related phenotypes and the ability to model pathogenesis and treatment of disease in iPSCs. Familial dysautonomia (FD) is a rare but fatal peripheral neuropathy caused by a point mutation in IKBKAP 8 involved in transcriptional elongation9. The disease is characterized by the depletion of autonomic and sensory neurons. The specificity to the peripheral nervous system and the mechanism of neuron loss in FD are poorly understood due to the lack of an appropriate model system. Here we report the derivation of patient specific FD-iPSCs and the directed differentiation into cells of all three germ layers including peripheral neurons. Gene expression analysis in purified FD-iPSC derived lineages demonstrates tissue specific mis-splicing of IKBKAP in vitro. Patient-specific neural crest precursors express particularly low levels of normal IKBKAP transcript suggesting a mechanism for disease specificity. FD pathogenesis is further characterized by transcriptome analysis and cell based assays revealing marked defects in neurogenic differentiation and migration behavior. Finally, we use FD-iPSCs for validating the potency of candidate drugs in reversing aberrant splicing and ameliorating neuronal differentiation and migration. Our study illustrates the promise of iPSC technology for gaining novel insights into human disease pathogenesis and treatment.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency.

            The purity of adeno-associated virus (AAV) vector preparations has important implications for both safety and efficacy of clinical gene transfer. Early-stage screening of candidates for AAV-based therapeutics ideally requires a purification method that is flexible and also provides vectors comparable in purity and potency to the prospective investigational product manufactured for clinical studies. The use of cesium chloride (CsCl) gradient-based protocols provides the flexibility for purification of different serotypes; however, a commonly used first-generation CsCl-based protocol was found to result in AAV vectors containing large amounts of protein and DNA impurities and low transduction efficiency in vitro and in vivo. Here, we describe and characterize an optimized, second-generation CsCl protocol that incorporates differential precipitation of AAV particles by polyethylene glycol, resulting in higher yield and markedly higher vector purity that correlated with better transduction efficiency observed with several AAV serotypes in multiple tissues and species. Vectors purified by the optimized CsCl protocol were found to be comparable in purity and functional activity to those prepared by more scalable, but less flexible serotype-specific purification processes developed for manufacture of clinical vectors, and are therefore ideally suited for pre-clinical studies supporting translational research.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Familial dysautonomia is caused by mutations of the IKAP gene.

              The defective gene DYS, which is responsible for familial dysautonomia (FD) and has been mapped to a 0.5-cM region on chromosome 9q31, has eluded identification. We identified and characterized the RNAs encoded by this region of chromosome 9 in cell lines derived from individuals homozygous for the major FD haplotype, and we observed that the RNA encoding the IkappaB kinase complex-associated protein (IKAP) lacks exon 20 and, as a result of a frameshift, encodes a truncated protein. Sequence analysis reveals a T-->C transition in the donor splice site of intron 20. In individuals bearing a minor FD haplotype, a missense mutation in exon 19 disrupts a consensus serine/threonine kinase phosphorylation site. This mutation results in defective phosphorylation of IKAP. These mutations were observed to be present in a random sample of Ashkenazi Jewish individuals, at approximately the predicted carrier frequency of FD. These findings demonstrate that mutations in the gene encoding IKAP are responsible for FD.
                Bookmark

                Author and article information

                Journal
                Hum Mol Genet
                Hum. Mol. Genet
                hmg
                Human Molecular Genetics
                Oxford University Press
                0964-6906
                1460-2083
                15 July 2018
                25 April 2018
                25 April 2018
                : 27
                : 14
                : 2466-2476
                Affiliations
                [1 ]Human Molecular Genetics Laboratory, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
                [2 ]Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy
                [3 ]Genethon and INSERM U951, Evry, France
                [4 ]Center for Genomic Medicine, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
                [5 ]Department of Biotechnology, Jožef Stefan Institute, Ljubljana, Slovenia
                [6 ]Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, Slovenia
                [7 ]Biomedical Research Institute BRIS, Ljubljana, Slovenia
                [8 ]University Pierre and Marie Curie and INSERM U974, Paris, France
                Author notes
                To whom correspondence should be addressed at: Human Molecular Genetics Laboratory, International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34149 Trieste, Italy. Tel: +39 0403757342; Fax: +39 040226555; Email: pagani@ 123456icgeb.org

                Irving Donadon and Mirko Pinotti authors contributed equally to this work.

                Article
                ddy151
                10.1093/hmg/ddy151
                6030917
                29701768
                6e533251-5d1e-41fe-beaa-5f9b12f88620
                © The Author(s) 2018. Published by Oxford University Press.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 16 January 2018
                : 12 April 2018
                : 16 April 2018
                Page count
                Pages: 11
                Funding
                Funded by: Telethon Foundation 10.13039/501100002426
                Award ID: GGP17006
                Funded by: Association Francais contre les Myopathies
                Award ID: 19500
                Funded by: Muscular Dystrophy Association 10.13039/100005202
                Award ID: 383229
                Funded by: National Institute of Health
                Award ID: R01NS095640
                Funded by: ICGEB institutional funds
                Categories
                Articles

                Genetics
                Genetics

                Comments

                Comment on this article